Alzheimer’s Blood Test: What p-tau217 Measures and Who It Is Really For

You may be here because of something very specific: a repeated question, a missed appointment or a growing difficulty with organisation in someone close to you. The possibility of resolving that worry with a blood test is compelling. It can also feel frightening.

p-tau217 is a real advance. In people with cognitive impairment, the best-validated assays can estimate Alzheimer pathology with accuracy once reserved for amyloid PET or cerebrospinal fluid. But it does not measure memory, explain a complaint by itself or issue a verdict about the future.

The useful question is not “Can I buy this test?” It is “What decision will the result change, and who will help me interpret it?”

The quick answer

Question	Answer
What does it measure?	A phosphorylated form of tau associated with Alzheimer biology. It does not measure memory or independence.
Who may benefit clinically?	Mainly people with objective cognitive impairment undergoing specialist assessment.
Does a positive mean dementia?	No. It means higher probability of pathology, not the severity or sole cause of impairment.
Does a negative end the workup?	Not always. Clinical suspicion, assay performance and agreement with other findings matter.
Can it screen healthy adults?	Not as routine care. Prognostic use in symptom-free people remains investigational.
Are all p-tau217 tests equivalent?	No. Platform, calibration, cutoff, performance and validated population vary.

p-tau217 without the jargon

Tau is a normal protein in neurons. In Alzheimer’s disease its phosphorylation changes, and abnormal tau eventually accumulates. p-tau217 means tau phosphorylated at the threonine 217 amino acid. Its blood concentration is closely related to the Alzheimer biological cascade, especially the accumulation of beta-amyloid.

There is more than one way to measure it. Some assays quantify p-tau217, others calculate its percentage relative to non-phosphorylated tau217, and the FDA-cleared device uses a p-tau217 to Aβ1-42 ratio. Values and cutoffs are not interchangeable. Sharing a biomarker name does not guarantee that two laboratories offer the same performance.

What FDA cleared, and what it did not clear

In May 2025, FDA cleared the Lumipulse G pTau217/β-amyloid 1-42 Plasma Ratio as an aid for detecting amyloid plaques. The intended population is specific:

• people aged 55 or older;
• with signs or symptoms of cognitive decline;
• assessed in a specialist setting;
• with results integrated with clinical information.

It was not cleared for population screening or as a stand-alone diagnosis. That distinction matters because the same result means something different at different pretest probabilities.

The evaluation used 499 samples from cognitively impaired adults. Among people with a positive result, 91.7% had amyloid plaques confirmed by PET or cerebrospinal fluid. Among those with a negative result, 97.3% were also negative on the reference test. Fewer than 20% had an indeterminate result.

Those are excellent results for this device and population. They should not be transferred to every commercial panel or a healthy person testing out of curiosity.

The guideline separates triage from confirmation

The 2025 Alzheimer’s Association guideline applies to people with objective cognitive impairment seen by clinicians experienced in memory disorders. It does not endorse one brand. It assigns a role according to test performance:

• Triage: an assay with at least 90% sensitivity and 75% specificity can help rule out pathology. A positive result needs confirmation with PET or cerebrospinal fluid.
• Confirmation: an assay with at least 90% sensitivity and 90% specificity can replace those reference tests in the appropriate specialist context.
• Intermediate zone: when two cutoffs protect certainty, some people are neither clearly positive nor clearly negative and need another test.

The guideline carries a simple warning: many marketed tests do not reach these thresholds. A comprehensive clinical assessment remains essential.

What accuracy studies tell us

In 2024, a study in the BioFINDER-2 and Knight ADRC cohorts evaluated percentage p-tau217. Among people with cognitive impairment, it classified amyloid PET status with roughly 89-90% accuracy. A two-cutoff strategy reached 95% while preserving intermediate results for confirmation.

In 2025, another study tested an automated platform in 1,767 people with cognitive symptoms. It included four hospital cohorts, one in Barcelona, and Swedish primary care. Accuracy was 89-91% in specialist care and 85% in primary care. Two cutoffs raised this to 92-94%, while 12-17% entered the intermediate zone.

The lesson is not that the test fails. It is that accuracy depends on the assay, setting and way cutoffs are used. The more certainty we demand, the more often a second test is needed.

Positive, negative and intermediate are not three diagnoses

If the result is high

It raises the probability of amyloid and tau pathology consistent with Alzheimer’s disease. It does not establish independent living ability, progression speed or the absence of other causes. Alzheimer pathology can exist without dementia, and more than one pathology can coexist.

If the result is low

On a high-sensitivity assay, it can make Alzheimer pathology unlikely and avoid more invasive tests. When the clinical pattern is strongly suggestive or the result conflicts with cognition and imaging, confirmation may still be needed.

If the result is intermediate

It does not mean “a little Alzheimer’s”. It means the assay cannot classify with the certainty required. The next step may be repeat testing, another biomarker, PET or cerebrospinal fluid.

Why symptom-free adults should not use it as a routine check

A 2026 study pooled 2,684 cognitively unimpaired older adults from six selected cohorts. Over a median 5.4 years, 478 progressed to cognitive impairment. Five-year risk was 24% in the high p-tau217 group and 38% in the very-high group.

This is important for prognostic models and trial design. It is not yet an individual prediction ready for routine care. The cohorts were not a random population sample, and the authors call for validation in unselected groups.

Before screening healthy people, we need to know how to disclose the result, what intervention to offer, how much psychological harm or diagnostic cascade it can create, and whether knowing improves health. Those questions remain open.

A positive result does not automatically explain a memory problem

Alzheimer pathology can coexist with vascular disease, Lewy body disease or other processes. Cognitive symptoms can also have treatable or modifiable contributors: sleep apnoea, depression, anxiety, alcohol, sedating or anticholinergic medicines, hypothyroidism, low B12, hearing loss, pain, infection or epilepsy.

Perimenopausal brain fog can be disruptive without representing dementia. Sleep problems also affect memory and attention. Taking symptoms seriously does not require labelling them too early.

A diagnostic path that starts with the person

1. Describe the change. What happens, when it began, who noticed it and how daily life is affected.
2. Establish whether it is objective. Use validated cognitive testing and neuropsychology when appropriate.
3. Look for alternatives and copathology. Review medicines, mood, sleep, hearing, laboratory markers, alcohol and vascular risk.
4. Use structural imaging when indicated. MRI or CT may reveal vascular disease, lesions or another cause.
5. Estimate pretest probability. Age, pattern and trajectory determine whether p-tau217 can answer a useful question.
6. Choose a validated assay. Platform, population, sensitivity, specificity and intermediate zone should be known.
7. Confirm when needed. PET or cerebrospinal fluid remains useful for discordance or treatment-sensitive decisions.
8. Disclose and decide. Translate the result into follow-up, safety, treatment or planning, not an isolated number.

p-tau217, APOE, PET and cerebrospinal fluid

Test	What it adds	What it cannot resolve alone
Blood p-tau217	Estimates Alzheimer pathology accurately in validated assays.	The complete cause of symptoms, clinical stage or individual prognosis.
APOE	Genetic risk and safety or eligibility information for some treatments.	It does not diagnose Alzheimer’s and has family implications.
Amyloid PET	Images cerebral amyloid burden and serves as a reference.	Access, cost, radiation and exact relationship to symptoms.
Cerebrospinal fluid	Measures amyloid and tau biomarkers and can confirm biology.	It requires lumbar puncture and preanalytical expertise.

Why anti-amyloid treatment makes context more important

In the European Union, lecanemab and donanemab are authorised for defined early stages of Alzheimer’s disease with confirmed amyloid pathology and restrictions related to APOE4. They are not preventive treatments for every adult.

A positive p-tau217 result does not automatically start treatment either. Clinicians must establish clinical stage and review genotype, MRI, microhaemorrhages, anticoagulants and monitoring capacity. Amyloid-related imaging abnormalities, known as ARIA, require careful selection and follow-up.

Ask these questions before paying

• Do I have objective cognitive impairment or an unevaluated concern?
• Which assay and platform will be used?
• Has it been validated in people like me and in this setting?
• What proportion of results is intermediate?
• Who will explain the result, and what support is available after a positive?
• What changes after a low, intermediate or high result?
• Will I still need PET, cerebrospinal fluid, MRI or APOE testing?

The rule is the same for every longevity biomarker: a measurement earns its place when it changes a useful decision and has a plan for unexpected results.

When not to wait for a biomarker

Sudden confusion, speech difficulty, one-sided weakness, a sudden severe headache, seizure, fever with drowsiness or a rapid behavioural change require urgent assessment. Alzheimer’s disease usually evolves progressively. An abrupt change calls for stroke, infection, medicines, metabolic disturbance or another acute cause to be considered first.

Frequently asked questions

Is there now a blood test for Alzheimer’s disease?

Validated blood assays can help detect amyloid pathology associated with Alzheimer’s disease. In 2025, FDA cleared a device for people aged 55 or older with signs or symptoms of cognitive decline. It is a diagnostic aid, not general screening or a stand-alone diagnosis.

What does a high p-tau217 result mean?

It raises the probability of amyloid and tau pathology consistent with Alzheimer’s disease. Meaning depends on the assay, cutoff, age, symptoms and pretest probability. It does not prove that Alzheimer pathology explains every symptom.

Does a normal p-tau217 result rule out Alzheimer’s?

A low result on a high-sensitivity assay can make Alzheimer pathology unlikely. If the clinical pattern remains suggestive, the result is intermediate or it conflicts with the rest of the assessment, PET, cerebrospinal fluid or another test may still be needed.

Can I take the test if I have no symptoms?

Routine screening is not recommended for people without symptoms. Prognostic research is advancing, but it does not yet provide sufficiently validated individual prediction or an indicated intervention for everyone with a high result.

Does a positive result mean that I have dementia?

No. A positive result indicates a higher probability of Alzheimer biology, not the level of function or the sole cause of symptoms. Pathology can exist without dementia, and vascular or other processes may coexist.

Is p-tau217 the same as APOE?

No. p-tau217 is a protein biomarker linked to Alzheimer pathology at the time of measurement. APOE is a genetic variant that modifies risk and the safety of some treatments. Neither should be interpreted without clinical context.

Can the test replace PET or lumbar puncture?

Some high-performing assays can replace them in specialist care, while others are triage tests that require positive results to be confirmed. Intermediate, discordant or treatment-critical results may still need PET or cerebrospinal fluid.

What should happen before p-tau217 is ordered?

First define the cognitive change, establish whether objective impairment exists and review medicines, mood, sleep, hearing, vascular risk, laboratory results and structural imaging when appropriate. Then decide whether the biomarker will answer a useful question.

Sources reviewed

• FDA, first blood-based device to aid Alzheimer diagnosis: indication, performance and limits.
• Alzheimer’s Association blood biomarker guideline: triage, confirmation and specialist care.
• DETeCD-ADRD guideline: comprehensive diagnostic assessment, disclosure and differential diagnosis.
• 2024 percentage p-tau217 study: comparison with PET and cerebrospinal fluid biomarkers.
• 2025 primary and specialist care study: automated platform, accuracy and two cutoffs.
• 2026 prognostic study in unimpaired adults: absolute risk and need for population validation.
• EMA, Leqembi: European indication and restrictions.
• EMA, Kisunla: European indication and restrictions.

p-tau217 can open a diagnostic door, but it cannot replace the conversation before it or the decisions after it. The good news is that a more accessible tool now exists. The responsible part is using it where it truly clarifies the path.